Charles Schwab Investment Management Inc Contrafect Corp Transaction History

Charles Schwab Investment Management Inc

  • $515 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$3.58 - $4.9 $140,590 - $192,427
-39,271 Reduced 66.65%
19,650 $87,000
Q1 2021

May 17, 2021
BUY
$4.46 - $6.68 $19,191 - $28,744
4,303 Added 7.88%
58,921 $283,000
Q3 2020

Nov 13, 2020
BUY
$5.05 - $6.99 $109,362 - $151,375
21,656 Added 65.7%
54,618 $289,000
Q2 2020

Aug 14, 2020
BUY
$4.69 - $7.81 $154,591 - $257,433
32,962 New
32,962 $211,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email